NCT01201278UnknownPhase 1
A Phase 1, Randomized, 3-Way Crossover, Investigator Initiated Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Two Doses of Intranasally Administered Regular Human Insulin Compared to a Single Dose of a Subcutaneously Injected Rapid Acting Insulin Analog (Humalog®) in Subjects With Type I Diabetes
Hompesch, Marcus, M.D.1 site in 1 country20 target enrollmentStarted: September 14, 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Insulin tolerability, PK, and PD
Study Overview
Brief Summary
This study is designed to compare the safety and tolerability of two different doses of intranasally administered regular human insulin with those of a single dose of the rapid-acting insulin analog lispro Humalog® after subcutaneous injection. In addition to safety and tolerability, various pharmacokinetic (PK) and pharmacodynamic (PD) parameters will be evaluated by means of the euglycemic glucose clamp technique.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female subjects with type 1 diabetes between the ages of 18 and 65 years, inclusive.
- •Type 1 diabetes clinically diagnosed ≥ 12 months.
- •Treated with multiple daily insulin injections ≥ 12 months or an insulin pump.
- •HbA1c ≤ 10 % by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive).
- •Fasting serum C-peptide ≤ 0.3 nmol/L.
- •BMI between 18-28 kg/m², inclusive.
- •Signed, written IRB-approved informed consent.
Exclusion Criteria
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, oncologic, or neurologic (to include history of seizures) disease; hypoglycemic episodes; intercurrent illness (such as influenza); or allergic disease (including severe drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Clinical significance to be determined by the PI.
- •History of recent nose bleed, history of nasal polyps, nasal surgery other than cosmetic rhinoplasty or cauterization.
- •As judged by the investigator, clinically significant findings in laboratory data. (Anemia with hematocrit less than 33% at screening is specifically exclusionary.)
- •Clinically significant abnormal ECG at screening, as judged by the Investigator.
- •Clinically significant abnormalities in vital signs at screening, as judged by the Investigator.
- •Known allergy to trial product or any other ingredient in the study drug.
- •Positive HIV 1 (human immunodeficiency virus) antibody test, hepatitis B (anti-HBsAg) or hepatitis C (anti-HCV) antibody test.
- •History or evidence of alcohol or drug abuse within the past 3 years.
- •History of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in 1st degree relatives (parents, siblings or children) as judged by the Investigator.
- •Use of drugs that may interfere with the interpretation of study results or are known to cause clinically relevant interference with insulin action or glucose utilization.
- •Blood donation or high volume phlebotomy, e.g., >500 mL, within 56 days before dosing.
- •Participation in a study of any investigational drug or device 30 days before enrollment in this study.
- •The subject is unfit for the study in the opinion of the investigator.
- •Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures include sterilization, hormonal intrauterine devices, oral contraceptives, sexual abstinence or vasectomized partner).
Arms & Interventions
Nasal insulin 8 IU
Experimental
Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
Intervention: Insulin (Drug)
Nasal insulin 16 IU
Experimental
Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
Intervention: Insulin (Drug)
Subcutaneous insulin lispro 8 U
Active Comparator
Subcutaneous insulin lispro (Humalog®) 8 U
Intervention: Insulin LISPRO (Drug)
Outcomes
Primary Outcomes
Insulin tolerability, PK, and PD
Time Frame: 120 minutes
To assess safety and tolerability, and to compare the insulin AUC over 0-120 min for each of the three insulin applications.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Acute Treatment Trial in Adult Subjects With MigrainesMigraineNCT03872453Pfizer2,154
Completed
Phase 1
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese SubjectsHealthyNCT02857777Janssen Research & Development, LLC37
Completed
Phase 1
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult ParticipantsHealthyNCT02345148Janssen Research & Development, LLC16
Completed
Phase 1
A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered EsketamineHepatic ImpairmentNormal Hepatic FunctionNCT02611505Janssen Research & Development, LLC24
Unknown
Not Applicable
Safety of intranasal palivizumab in healthy adult volunteersRSVNL-OMON23479ouis Bontl.bont@umcutrecht.nl